SEC Form 4 · accession 0001454983-26-000008
Kiniksa Pharmaceuticals International, plc · KNSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard S Levy
Director
Period of report
Aug 1, 2026
Accepted (ET)
Aug 4, 2026 · 4:40 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001730430
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary ShareF1 | Aug 1, 2026 | M | 403 | — | A | 22,359 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1,F2 | — | Aug 1, 2026 | A | 403 | A | — | — | Class A Ordinary Shares | 403 | 403 | D |
| Restricted Share UnitsF1,F2 | — | Aug 1, 2026 | M | 403 | D | — | — | Class A Ordinary Shares | 403 | 0 | D |
Explanation of responses
- F1Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- F2The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs.